

MEDICIS PHARMACEUTICAL CORP

Form 8-K

August 29, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 23, 2007
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)**

Delaware
(State or other jurisdiction of
incorporation)

0-18443
(Commission
File Number)

52-1574808
(IRS Employer
Identification No.)

**8125 North Hayden Road
Scottsdale, Arizona 85258-2463**
(Address of principal executive offices) (Zip code)
(602) 808-8800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-99.1

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement

On August 23, 2007, Ucyglyd Pharma, Inc. (Ucyglyd), a Maryland corporation and wholly-owned subsidiary of Medicis Pharmaceutical Corporation, a Delaware corporation (the Company), and Hyperion Therapeutics, Inc., a Delaware corporation (Hyperion), executed a Collaboration Agreement (the Agreement), pursuant to which Hyperion will continue the ongoing research and development of Ucyglyd's product referred to as GT4P for the treatment of Urea Cycle Disorder (UCD), Hepatic Encephalopathies (HE) and other indications, and additional indications for AMMONUL® (collectively, the Research Projects). In addition, Hyperion will co-promote Ucyglyd's existing on-market products AMMONUL® and BUPHENYL® (the Existing On-Market Products) for the treatment of UCD. In exchange for the rights and licenses granted to Hyperion under the Agreement, Hyperion will pay Ucyglyd a fee of \$10 million. Moreover, if certain conditions are satisfied relating to the Research Projects, Hyperion will be entitled to certain buyout rights to Ucyglyd's development products and Existing On-Market Products, and will pay Ucyglyd royalties and regulatory and sales milestone payments in connection with certain licenses that would be granted to Hyperion upon exercise of such buyout rights with respect to GT4P for various indications and AMMONUL® for HE.

On August 28, 2007, the Company and Hyperion issued a joint press release announcing the strategic collaboration between Hyperion and Ucyglyd. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) *Exhibits.*

Exhibit Description

99.1 Joint press release, dated August 28, 2007, announcing the strategic collaboration between Hyperion and Ucyglyd.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL
CORPORATION

Date: August 29, 2007

/s/ Mark A. Prygocki, Sr.
Mark A. Prygocki, Sr.
Executive Vice President, Chief Financial
Officer and Treasurer

Table of Contents

EXHIBIT INDEX

Exhibit	Description
99.1	Joint press release, dated August 28, 2007, announcing the strategic collaboration between Hyperion and Ucyclid.